Beam Therapeutics Inc. (BEAM) has a negative trailing P/E of -33.5, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -2.98%.
Criteria proven by this page:
Overall SharesGrow Score: 53/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2017 | -27.8 | 0.00 | -58.06 | 0.00 | - |
| 2018 | -5.7 | -0.01 | 4.92 | 0.00 | - |
| 2019 | -12.3 | 0.23 | 9.54 | 53,478.86 | - |
| 2020 | -19.6 | -0.08 | 15.54 | 158,970.84 | - |
| 2021 | -13.8 | -2.71 | 6.19 | 98.73 | - |
| 2022 | -9.5 | 0.33 | 3.73 | 44.95 | - |
| 2023 | -15.8 | 0.27 | 2.14 | 5.56 | - |
| 2024 | -5.4 | -0.03 | 2.78 | 32.14 | - |
| 2025 | -34.3 | 0.42 | 2.21 | 19.62 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2017 | $-0.62 | $0.00 | $-8M | - |
| 2018 | $-3.28 | $0.00 | $-115.26M | - |
| 2019 | $-1.53 | $18K | $-78.44M | -435788.9% |
| 2020 | $-5.49 | $24K | $-256.42M | -1068433.3% |
| 2021 | $-5.31 | $51.84M | $-341.36M | -658.4% |
| 2022 | $-3.76 | $60.92M | $-263.59M | -432.7% |
| 2023 | $-1.72 | $377.71M | $-132.53M | -35.1% |
| 2024 | $-4.58 | $63.52M | $-376.74M | -593.1% |
| 2025 | $-0.81 | $139.74M | $-79.99M | -57.2% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-4.38 | $-5.95 – $-0.52 | $44.64M | $20.1M – $78.66M | 13 |
| 2027 | $-4.51 | $-7.15 – $-0.49 | $59.48M | $22.58M – $102.33M | 12 |
| 2028 | $-4.53 | $-7.57 – $-2.81 | $116.34M | $112.58M – $120.11M | 11 |
| 2029 | $-3.13 | $-7.29 – $-1.01 | $399.48M | $191.66M – $809.1M | 4 |
| 2030 | $-1.11 | $-2.58 – $-0.36 | $712M | $341.59M – $1.44B | 4 |
